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Abstract
Background/Aim. Melanoma is a heterogeneous disease
of skin and mucous membranes which shows significant in-
crease in incidence worldwide in the past decades. In the
process of forming new blood vessels stimulators of angio-
genesis participate. There is an increase production of vas-
cular endothelial growth factor (VEGF-C and VEGF-D),
which expression cause change of endothelial cells, and
higher degree of tumor's aggressiveness. The aim of this re-
search was to determine the level of VEGF expression in
skin melanoma in different body regions and in different
primary stages of the disease. Methods. The research was
conducted on bioptic materials of skin in 39 patients. On
excision-made materials a routine histological preparation
was done and following parameters were determined: his-
tological type, alteration thickness (according to Breslow),
Clark level, TNM (Tumor Nodus Metastasis) stage (pT), al-
teration width, thickness of lymphocytic infiltration in the
tumor, mitotic index, phase of the tumor growth, presence
of ulcerations, cellular type of the tumor, localization and
level of VEGF expression. Results. Analysis confirmed
that 61.54% of skin melanoma showed a high VEGF ex-
pression. Nodular and acral lentiginous melanomas showed
more frequently a high level of VEGF expression, while su-
perficial spreading melanoma showed a lower level of
VEGF expression (p = 0.032, p < 0.05). A higher level of
expression was present in thicker melanomas (higher in the
Breslow stage; p = 0.011, p < 0.05). The width of the lesion
did not have an influence on the level of VEGF expression
in melanoma (U =142.000, p =  0.273). Conclusion. Mela-
nomas show a higher level of VEGF expression. Nodular
and acral lentiginous types of melanoma show a high level
of VEGF expression, while superficial spreading melanoma
shows a lower level of VEGF expression. Melanomas in
higher-stage disease (Breslow, Clark, pTNM) show a higher
level of VEGF expression.
Key words:
melanoma; neoplasm staging; angiogenesis inducing
agents; vascular endothelial growth factor; histological
techniques.
Apstrakt
Uvod/Cilj. Melanom je heterogeno oboljenje kože i sluzni-
ca koje u posljednjim decenijama pokazuje izrazito poveća-
nje incidencije u celom svetu. U procesu nastanka novih kr-
vnih sudova učestvuju stimulatori angiogeneze. Povećava se
produkcija vaskularnog endotelnog faktora rasta (VEGF-C i
VEGF-D) čijom ekspresijom dolazi do promene endotelnih
ćelija što za posledicu može imati veći stepen agresivnosti
tumora. Cilj istraživanja bio je da se utvrdi stepen ekspresije
VEGF u melanomima kože različitih regija u različitim pri-
marnim stadijumima bolesti. Metode. Istraživanje je obu-
hvatalo biopsijske materijale kože 39 bolesnika. Na materi-
jalima koji su dobijeni ekscizijom urađena je rutinska histo-
loška obrada i određeni su sledeći parametri: histološki tip,
debljina promene (Breslow), Clark nivo, TNM (tumor no-
dus metastaza) stadijum (pT), širina promene, gustina limfo-
citnog infiltrata u tumoru, mitotski indeks, faza rasta tumo-
ra, prisustvo ulceracije, ćelijski tip tumora, lokalizacija i ste-
pen ekspresije VEGF. Rezultati. Analizom je utvrđeno da
61,54% melanoma kože pokazuje visoku ekspresiju VEGF.
Nodularni i akralni lentiginozni tip melanoma češće poka-
zuju visoki stepen ekspresije VEGF, a površinski šireći me-
lanom češće niski stepen ekspresije VEGF (p = 0,032, p <
0,05). Viši stepen ekspresije prisutan je u melanomima koji
su deblji (viši stadijum prema Breslow) (p = 0,011, p < 0,05).
Širina lezije ne utiče na stepen ekspresije VEGF u melano-
mu (U = 142,000, p = 0,273). Zaključak. Melanomi poka-
zuju visok stepen ekspresije VEGF. Nodularni i akralni len-
tiginozni tip melanoma pokazuju visoku ekspresiju VEGF, a
površinski šireći melanom pokazuje nisku ekspresiju VEGF.
Melanomi u višem stadijumu bolesti (Breslow, Clark, pT)
pokazuju veći stepen ekspresije VEGF.
Ključne reči:
melanom, maligni; neoplazme, određivanje stadijuma;
angiogeneza, induktori; faktori rasta endotela krvnih
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Introduction
Melanoma is a heterogeneous disease of the skin and
mucous membranes which shows a significant increase in
worldwide incidence in the past decades (from 2.7 to 6.0 on
100 000 residents per year in men and from 4.6 to 8.5 on
100  000 residents in women). The total incidence is the
highest in Australia and between 1980 and 1990 it tripled  
1,
2. Risk factors for the onset and development of melanoma
are numerous, but the most frequently mentioned is exposure
to sunlight 
3, 4.
Melanoma is more likely to occur on the head, neck and
trunk in men and the lower leg in women 
5, 6. The two phases
of tumor progression are described: radial and vertical phase
of the melanoma growth. On the basis of clinical and bio-
logical characteristics the World Health Organization
(WHO) has offered the classification of melanoma where are
(because of the frequency) particularly described the superfi-
cial spreading melanoma, nodular and acral lentiginous
melanoma 
7.
Angiogenesis implies the creation of new capillary
blood vessels from the existing vascular network and is a
very complex process that involves extravasation of proteins
and plasma, decomposition of extracellular matrix, migration
and proliferation of endothelial cells and forming of capillary
tubes 
8. All processes that occur during this angiogenic cas-
cade are regulated by various factors, stimulators and in-
hibitors whose balance limits the process 
9.
Stimulators of angiogenesis are: growth factor of en-
dothelial cells of blood vessels (VEGF), basic and acidic fi-
broblast growth factors (b-FGF, aFGF, FGF-2, FGF-1), en-
dothelial cell growth factor originating from platelets (PD-
ECGF), angiopoetin-1 and others 
10, 11. VEGF is a soluble
homodimeric glycoprotein that binds to the receptors with ty-
rosine kinase activity on endothelial cells 
12, 13. Five subtypes
of VEGF with different molecular weight are described.
Among them, VEGF-B (23 kd) and VEGF-C (34 kd) have a
significant place 
13, 14. Angiogenesis in the skin is regularly
associated with an increased expression of VEGF in epider-
mal keratinocytes 
15. Explanation of why melanoma spreads
faster in lymphogenic than hematogenic pathway is given by
the information about the increased production of factors
VEGF-C and VEGF-D, whose expression changes endothe-
lial cells in the lymph vessels and consequently there is an
increase of the degree of tumor progression 
16, 17. VEGF is
required in the process of angiogenesis because it represents
a specific mitogen for endothelial cells, allows their migra-
tion and increases the permeability of blood vessels 
11.
Data from the literature indicate a low level of expres-
sion of VEGF in benign melanocyte alterations (nevi). The
authors suggest that increased expression of VEGF in dys-
plastic nevi may be an indicator of preneoplastic alterations
in melanocyte lesions 
18. A group of authors stated that esti-
mation of VEGF expression might help in differential diag-
nosis among dysplastic nevi and melanoma and that VEGF
may be a “candidate for targeted treatment” 
19. Piscane and
Risio 
20 have found expression of VEGF and VEGFR-2 in
benign and malignant melanocyte alterations. They have
found that cytoplastmatic and nuclear membrane expression
of VEGFR-2 is associated with progression of melanocyte
lesions to invasive melanoma.
Melanocyte alterations show expression of VEGF, re-
gardless of clinical behavior: benign melanocyte alterations
more often indicate a low level of VEGF expression and ma-
lignant melanocyte alterations more often show a high level
of VEGF expression 
21.
Inhibitors of angiogenesis are thrombospondins (TSP),
angiostatin, platelet factor 4 (PF 4), angiostatic steroids and
some other substances 
22–24.
Numerous diseases in dermatology, including malig-
nant neoplasms, have factors of stimulation or inhibition of
angiogenesis as an important component, which could in the
future enable the effective treatment of patients suffering
from these diseases 
25. Targeted treatment with angiogenesis
inhibitors decreases the possibility of creating new blood
vessels in tumor, and thus indirectly affects tumor cells and
slows tumor growth and development 
26.
Angiogenic factors exhibit their effects on endothelial
cells directly or indirectly. Highly vascularized tumors have
a higher metastatic potential compared to less vascularized
tumors, and researches show that the number of metastases is
directly proportional to the number of released tumor cells in
circulation 
27. Angiogenesis is a necessary step for the onset
and for the end of the metastatic process. With vasculariza-
tion of the primary tumor begins expansive growth and tu-
mor gets metastatic potential 
28–30.
The aim of this study was to determine the level of
VEGF expression in melanoma of the skin of different re-
gions, and to determine the correlation between the level of
VEGF expression and morphologic prognostic parameters
(histological type, ulceration, inflammatory infiltrate density,
mitotic index, stage of disease, stage of growth and cell
type).
Methods
The research included bioptic materials of the skin of
39 patients, performed in the Clinical Center of Banja Luka
in the period from 2004 to 2007. Histological analysis estab-
lished the diagnosis of skin melanoma (primary skin mela-
noma).
In all subjects we determined: histological type by
analysing of histological samples according to the WHO
histological classification 
7; thickness change (Breslow),
measured vertically in millimeters from the granular layer of
the epidermis to the place of deepest invasion, or from the
base of the defect to the place of deepest invasion; Clark
level histologically and by the layers of tumor location (level
I to level V) 
7; pTNM stage on the basis of histological
analysis and insight into the history of the disease, according
to the 7th pTNM classification 
29, 30; width of the lesion mi-
croscopically in millimeters, from one side edge of the al-
teration to the other side edge; tumor infiltration by lympho-
cytes (absent – no lymphocytes in the tumor stroma; rare in-
filtrate present – from 1 to 10 lymphocytes on one visual
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ent – from 11 to 20 lymphocytes on one visual field in high
magnification; dense infiltration present – more than 20 lym-
phocytes on one visual field in high magnification). Assess-
ment was done in the stroma of the tumor and on the border
of the tumor and surrounding tissue; mitotic index: the num-
ber of mitosis was determined in 10 visual fields in high
magnification. The width of visual field was 1.4 mm. Visual
fields which were quantified represent the peripheral parts of
the tumor (to the surrounding tissue); estimation of growth
phase: radial growth phase – present or absent (lentigo ma-
lignant, acral lentiginous, superficial spreading type); vertical
growth phase – present or absent (expansive tumor clusters
located in the papillary and / or reticular dermis) 
7; the pres-
ence of ulceration: assessed histologically based on the con-
tinuity of the epidermis above the lesion (present or absent
ulceration); cell type of the tumor: epitheloid cells, spindle
cells, mixed type (epitheloid + spindle cells); localization:
alterations were classified according to localization into the
following subgroups: head and neck, trunk, extremities; ex-
pression of VEGF: assessment of expression from 0 to 3.
Epitope demasking was performed by pretreatment in a
microwave oven and by soaking of slides in Target Retrival
Solution pH 9.0 (Daco S2367). As the primary antigen we
used commercial mouse monoclonal anti-human VEGF anti-
body (Daco M7273), the concentration of VG1 with 1:25
dilution. For visualization we used the LSAB + (Daco
K0690) system and hromogen DAB Liquid (K3466).
The presence or absence of factors and the intensity of
their presence was valued by a semiquantitative scale from 0
to 3, taking as an internal control level of immunostaining of
keratinocytes.
Quantification was as follows: score 0  – no difference
in immunostaining for VEGF between melanocytes and ke-
ratinocytes; score 1 to 3 – a higher level of VEGF expression
in tumor cells compared to keratinocytes; score 1 – less than
25% tumor cells showed expression of higher intensity com-
pared with the level of staining of keratinocytes; score 2 – 25
to 75% of tumor cells showed expression of higher intensity
compared with the level of staining of keratinocytes; score 3
– more than 75% tumor cells showed expression of higher
intensity compared with the level of staining of keratino-
cytes.
The results were analyzed by methods of descriptive
and correlative statistics. Statistical analysis was performed
using the SPSS software version 15.0, and the following tests
were applied: χ
2 and the related methods of analysis of cate-
gorical variables (Fisher's exact test, Kendall's Tau test) and
Mann Whitney U- test.
Results
Our research was done on bioptic materials of 39 pa-
tients (23 women and 16 men) performed in the Clinical
Center of Banja Luka in the period from 2004 to 2007. Based
on the analyzed materials a diagnosis of primary melanoma
of the skin was established.
The youngest examinee was 18 years old and the oldest
one 85 years. The average age of all examinees was 58.66
years. Melanomas in our material belonged to the following
histologial types: nodular type in 31 (79.49%) cases, superfi-
cial spreading melanoma of the in 6 (15.38%) cases and acral
lentiginous type in 2 (5.13%) cases.
Characteristics of examinees are presented in Table 1.
The study found that a low level of expression of VEGF
was present in 38.46% of the cases – level 0 and 1, while a
high level of expression was present in 61.54% of the cases –
level 2 and 3 (Table 2) (Figures 1 and 2). More often, a high
expression of VEGF was verified (score 2 and 3 – χ
2 = 8.487
with a df 3; p = 0.037, p < 0.05).
Fig. 1 – High level of VEGF expression in melanoma, score 2
(anti-VEGF; ×400)
Fig. 2 – High level of VEGF expression in melanoma, score 3
(anti-VEGF; ×200)
Table 2 presents the relationship between histologic
type of melanoma and expression of VEGF in accordance
with the WHO classification. There was a statistically sig-
nificant difference in the level of VEGF expression in mela-
noma due to the histological type. Nodular and acral lentigi-
nous type of melanoma more often showed a high level of
expression of VEGF, while superficial spreading melanoma
often showed a low level of VEGF expression (χ
2 = 6.858
with a degree of freedom df = 2, p = 0.032, p < 0.05).Strana 750 VOJNOSANITETSKI PREGLED Volumen 67, Broj 9
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FThe presence of defects (ulcerations) in the epidermis
was verified in 22 (56.41%) of the cases. Table 2 shows the
relationship between VEGF expression and the presence or
absence of ulcerations. There was a statistically significant
difference in the level of VEGF expression and the presence
of ulcerations – χ
2 = 4.545 with a degree of freedom (df) 1
where p = 0.033 (p < 0.05). In the cases of verified ulcera-
tions, the level of VEGF expression was mainly high score, 2
and 3.
The average value of Breslow level (thickness of le-
sion) in melanoma with the level of immunostaining 0 for
VEGF was 4.25 mm, with the level 1 of immunostaining
for VEGF was 5.37 mm, with the level 2 was 4.23 mm, and
for melanomas with the level 3 of immunostaining for
VEGF mean value of Breslow level was 14.51 mm (Table
3). Based on the analysis by χ
2 test we could conclude that
there was a statistically significant difference in the level of
VEGF expression and thickness of the lesion in skin mela-
nomas – χ
2 =  11.211 with the degree of freedom df = 3
where p = 0.011 (p < 0.05). A higher level of expression
was present in thicker melanomas (higher level according
to Breslow).
In melanoma with level 0 of immunostaining of VEGF,
level of invasion according to Clark was IV in one of the
cases, and V in the other one. In melanomas with the level of
immunostaining 1 for VEGF, the level of invasion according
to Clark was II in 3 of the cases (23.07%), III in 4 of the
cases (30.76%), IV in 3 of the cases (23.07%), and V in 3
cases (23.07%). In melanomas with level 2 of immunostain-
ing for VEGF, the level of invasion according to Clark was II
in 2 of the cases (15.38%), III in 4 of the cases (30.76%), IV
in 5 of the cases (38.46%), and V in 2 of the cases (15.38%).
Table 1
Characteristics of the examinees
Characteristics Years Number of examinees
Age average 58.66
Localization
head and neck
trunk
extremities
13
11
15
Histologic type of melanoma
nodular
superficial spreading
acral lentiginous
31
6
2
Ulceration
present
absent
22
17
Mitotic activity /10HPV
0–5
6–10
>10
15
11
13
Clark
I
II
III
IV
V
0
5
8
14
12
Breslow
I (0–0.75 mm)
II (0.76–1.50 mm)
III (>1.50 mm)
2
5
32
TNM
pT1a
pT1b
pT2a
pT2b
pT3a
pT3b
pT4a
pT4b
2
1
4
2
4
6
5
15
Growth phase
radial
vertical
vertical and radial
1
25
13
Level of VEGF expression
0
1
2
3
2
13
13
11
TNM – Tumor Nodus Metastasis; VEGF – vascular endothelial growth factorVolumen 67, Broj 9 VOJNOSANITETSKI PREGLED Strana 751
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In melanomas with the degree 3 of immunostaining for
VEGF, the level of invasion according to Clark was IV in 6
of the cases (54.54%), and V in remaining 5 of the cases
(45.45%). Based on the analysis by Kendall's tau b test, no
statistically significant difference was found in the level of
VEGF expression and level of invasion according to Clark
(Kendall's tau b = 0.244, p = 0.063).
Table 2 presents the results of the level of expression of
VEGF and the TNM (pT) stage of melanoma. A higher level
of expression was present in melanoma in advanced stage of
the disease. Statistical analysis using Kendall's tau c test
showed that there was a statistically significant difference in
the level of expression of VEGF and pT stage of melanoma
(Kendall's tau c t = 0.259, p = 0.050 and p < 0.05). Melano-
mas in higher pT stage of the disease showed a higher ex-
pression of VEGF (score 2 and 3).
The average value of width of lesion for melanomas
with the level of immunostaining 0 for VEGF was 8.6 mm.
The average width of melanoma lesion with the level 1 of
immunostaining for VEGF was 14 mm, with level 2 mean
lesion width was 9.91 mm, and in melanoma with the level 3
of immunostaining for VEGF average lesion width was
Table 2
Relationship of  level of VEGF expression and prognostic parameters in melanoma
Level of immunostaining for VEGF
01 2 3 Prognostic parameters
in melanoma
2 (5.13%) 13 (33.33%) 13 (33.33%) 11 (28.21%)
Histologic type
nodular 2 (6.45%) 8 (25.81%) 11 (35.48%) 10 (32.26%)
superficial 5 (83.33%) 1 (16.67%)
spreading
acral
lentiginous 1 (50%) 1 (50%)
Presence of ulceration
present 1 (4.54%) 5 (22.73%) 7 (31.82%) 9 (40.91%)
absent 1 (5.88%) 8 (47.06%) 6 (35.29%) 2 (11.77%)
TNM
pT1a 2 (15.38%)
pT1b 1 (7.69%)
pT2a 2 (15.38%) 2 (15.38%)
pT2b 1 (7.69%) 1 (7.69%)
pT3a 1 (50%) 2 (15.38%) 1 (9.09%)
pT3b 5 (38.46%) 1 (9.09%)
pT4a 3 (23.07%) 1 (7.69%) 1 (9.09%)
pT4b 1 (50%) 4 (30.76%) 2 (15.38%) 8 (72.72%)
Density of lymphocytic infiltrate
dense infiltrate 2 (8%) 12 (48%) 5 (20%) 6 (24%)
medius dense infiltrate 1 (12.5%) 4 (50%) 3 (37.5%)
rare infiltrate 3 (60%) 2 (40%)
Mitotic activity
0–5/10HPF 8 (53.33%) 5 (33.33%) 2 (13.34%)
6–10/10HPF 1 (9.09%) 3 (27.27%) 4 (36.37%) 3 (27.27%)
> 10/10HPF 1 (7.96%) 2 (15.38%) 4 (30.77%) 6 (46.16%)
Growth phase
radial 1 (4%) 6 (24%) 11 (44%) 7 (28%)
vertical 1 (100%)
vertical and radial 1 (7.69%) 6 (46.16%) 2 (15.38%) 4 (30.77%)
Cell type
epitheloid 1 (3.22%) 12 (38.71%) 10 (32.26%) 8 (25.81%)
spindle 1 (20%) 1 (20%) 1 (20%) 2 (40%)
mixed 2 (66.67%) 1 (33.33%)
Localization
head and neck 1 (7.69%) 7 (53.85%) 3 (23.07%) 2 (15.39%)
trunk 5 (45.46%) 3 (27.27%) 3 (27.27%)
extremities 1 (6.67%) 1 (6.67%) 7 (46.66%) 6 (40%)
TNM – Tumor Nodus Metastasis; VEGF – vascular endothelial growth factor
Table 3
Relationship between the level of VEGF expression and average thickness and width of melanoma
Level of immunostaining for VEGF Characteristics of melanoma 01 2 3
Average thickness (mm) 4.25 5.37 4.23 14.51
Average width (mm) 8.6 14 9.91 28.47
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28.47 mm (Table 3). Based on statistical analysis using
Mann-Whitney test, we concluded that there was no statisti-
cally significant difference in the level of expression of
VEGF and width of lesions in melanomas (U = 142.000, p =
0.273).
In the analyzed material inflammation infiltrate was
present in 38 (97.44%) cases. Inflammation infiltrate was
generally dense (Table 2). In case of low expression of
VEGF (score 0 and 1) there was usually dense inflammation
infiltrate in 14 (93.33%) of the cases. Dense inflammation
infiltrate was also present in most of the cases of high ex-
pression of VEGF (score 2 and 3), in 11 (47.83%) of the
cases. On the basis of statistical analysis it was concluded
that there was a statistically significant difference in the level
of expression of VEGF and the density of lymphocyte infil-
trates – χ
2 =
 8.555 with a degree of freedom (df) 2 where p =
0.014 ( p < 0.05). The low level of expression of VEGF was
more often verified in melanomas with dense lymphocyte in-
filtrate, and high level of expression was verified in melano-
mas with rare lymphocyte infiltrate.
In our research measuring of mitotic activity in 10 con-
secutive visual fields in high magnification was done. Re-
garding the mitotic activity, alterations were divided into
three categories: 0 to 5/10HPF, from 6 to 10/10HPF, and 11
and over /10HPF. Relationship of VEGF expression and
mitotic activity of tumor cells was shown in Table 2. Based
on Kendall's tau-c test, we found that there was no statisti-
cally significant difference in the level of VEGF expression
in relation to the level of mitotic activity (Kendall's tau c t =
0.256, p = 0.060).
Melanocyte malignant alterations (melanomas) in our
material were in advanced stages, and in most cases were in
vertical growth phase. Dominantly vertical growth phase was
verified in 25 (64.1%) of the cases. The presence of vertical
and radial growth phase was verified in 13 (33.33%) of the
cases. In one of the cases (2.56%) only radial growth phase
was verified. Table 2 shows the relationship between the
level of VEGF expression and stage of tumor growth. On the
basis of statistical analysis we concluded that there was a
statistically significant difference in the level of VEGF ex-
pression and growth phase of melanoma. Melanomas with
the present vertical growth phase showed a higher level of
expression of VEGF – χ
2 = 4.840 with a degree of freedom
(df) 1 where p = 0028 (p<0.05).
The cells had an epithelioid appearance in 31 (79.49%)
of the cases. Spindle cells were present in 5 (12.82%) of the
cases and mixed type (epithelioid and spindle cells) were
verified in 3 (7.69%) of the cases. Table 2 shows the rela-
tionship between the level of VEGF expression and cell type
of melanoma. Analysis by χ
2 test showed a statistically sig-
nificant difference in the level of VEGF expression and cell
type of melanoma – χ
2 = 8.871 with a degree of freedom (df)
3 where p = 0.031 (p < 0.05). A high level of VEGF expres-
sion was often verified in melanomas with epithelioid cells.
Melanoma in the examined material was mainly local-
ized on extremities in 15 (38.46%) of the cases, followed by
the field of head and neck in 13 (33.33%) of the cases and on
the trunk in 11 (28.21%) of the cases. Relationship of VEGF
expression and localization of the melanoma is shown in ta-
ble 2. Based on the analysis by χ
2 test, was a statistically sig-
nificant difference in the level of VEGF expression and lo-
calization of the melanoma – χ
2 = 7.831 with a degree of
freedom (df) 3 where p = 0.05 (p < 0.05). Melanoma local-
ized on the extremities showed a higher level of expression
of VEGF (score 2 and 3), while melanoma localized on the
head, neck and trunk showed a low level of expression of
VEGF.
Discussion
This study included a total of 39 melanomas. A low
level of expression of VEGF was present in 38.46% of the
cases (score 0 and 1), while a high expression was present in
61.54% of the cases (score 2 and 3). Caraza and Peyri 
31 in
their research state that the majority of melanomas show a
lower level of expression (score 0 and 1), which is different
compared with our results. A logical explanation of this dif-
ference is that these authors have studied a selected group of
melanomas (“thin melanoma”, ie Breslow less than 1 mm),
while in our research we studied the unselected group of
melanomas. As an alternative, two different research groups
describe alternative mechanisms for traditional angiogenesis
which melanoma cells use to reach the vascular circulation:
Leeners tells about “vascular co-option” or that melanoma
uses the blood vessels that existed earlier in the animal
model of cerebral metastatic melanoma, and Folberg de-
scribes “vasculogenic mimicry”, which primary cutaneous
melanoma use to create three-dimensional structures that
function as blood vessels, without a real angiogenesis 
32, 33.
In our research nodular and acral lentiginous types of
melanoma more often showed a high level of expression of
VEGF, and superficial spreading melanoma more often had a
low level of expression of VEGF. The results are in line with
the literature data 
31.
In our research there was a statistically significant dif-
ference in level of VEGF expression and the presence of ul-
ceration and thickness according to Breslow. Boone et al.  
34
in their study did not manage to prove a positive correlation
between expression of VEGF-C factor and the presence of
ulceration, tumor thickness according to Breslow, and the
level of invasion according to Clark.
In our material there were malignant alterations in
Clark level I. A higher number of melanoma cases showed a
high expression of VEGF (score 2 and 3) in 24 (61.54%) of
the cases. Cases with higher degree of expression are gener-
ally in higher Clark level. Based on the analysis by Kendall's
tau-b test, there was no statistically significant difference in
the level of VEGF expression and level of invasion accord-
ing to Clark. Salven et al. 
14 also failed to found differences
in manifestation of VEGF measured by immunohistochemi-
cal methods between smaller and larger primary melanomas.
However, this is not what all authors agree about: Redondo
et al. 
35 believe that the more the Clark's or Breslow's level
increases, the percentage of positive immunostaining for
VEGF also increases, linking it with the development of the
primary tumor, but no prognostic research was done.Volumen 67, Broj 9 VOJNOSANITETSKI PREGLED Strana 753
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Melanocyte malignant alterations (melanoma) in our
material were in advanced stages, and in most of the cases
were in the vertical growth phase. Dominantly vertical
growth phase was verified in 25 (64.1%) of the cases. On the
basis of statistical analysis, there was a significant difference
in the level of VEGF expression and growth phase of mela-
noma. Melanoma with a vertical growth phase showed a
higher level of VEGF expression. Looking at the value of
immunostaining of VEGF against the Breslow level, a very
important item was found: melanomas in radial stage
changing to the malignant eclipse manifested less VEGF,
which was significantly different measured by the precise
Fisher test (p = 0.002) compared to already penetrated mela-
nomas 
36. Erhard et al. 
27 describe the same findings: larger
angiogenesis in the vertical phase compared to the radial one
and higher manifestation of VEGF. Later, Bayer-Garner et
al. 
37 found a less manifestation of VEGF measured by im-
munohistochemical methods in melanomas in radial phase
compared to melanomas in vertical phase found. VEGF was
not the only angiogenic factor for which these data were ob-
served. Bachelot et al. 
22, using in situ hybridization, showed
low manifestation of bFGF-a7 in melanomas in situ, com-
pared with its higher manifestation in invasive melanomas.
In this way, both studies support the importance of these
factors in transition of melanoma from radial to vertical
growth phase. Also it should be emphasized that bFGF and
VEGF act synergically as activators in angiogenic process 
38.
VEGF would thus often been absent or could be manifested
minimally in skin melanoma in radial stage. These melano-
mas are indolent and their extirpation assumes the probabil-
ity of healing of almost 100%. The reason is their inability to
form metastases. At a time when neoplastic cells manage to
manifest angiogenic factor, this will provide them with a fa-
vorable microambient by increasing vascular permeability in
melanoma as a necessary precondition for the development
of the tumor. In addition, a factor directly stimulates angio-
genesis and the arrival of multiple macromolecules essential
for the metastatic cascade due to the increase of permeabil-
ity. Even hypothetically speaking, VEGF could even more
stimulate autocrine growth of melanoma cells if they exhibit
kdr receptor, a phenomenon that was previously described in
medical literature (specifically, in A375P line of melanoma
in humans and its derivatives A375MM) 
39.
Conclusion
Melanomas show a high level of VEGF expression.
Nodular and acral lentiginous types of melanoma show a
high expression of VEGF, and superficial spreading melanoma
shows a low expression of VEGF. Melanomas with ulceration,
with rare inflammation infiltrate in the stroma, high mitotic in-
dex, and melanomas in a higher stage of disease (Breslow,
Clark, pTNM) show a higher level of expression of VEGF.
Melanomas in radial phase of growth show a low level
of expression of VEGF and melanomas in vertical growth
phase showed a high level of expression of VEGF. Epithe-
lial-cellular melanomas and melanomas localized on ex-
tremities show a higer level of VEGF expression.
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